Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Not Confirmed
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Not Confirmed
Not Confirmed
12-14 January, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Tides Asia
Not Confirmed
Contact SupplierTides Asia
Industry Trade Show
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Industry Trade Show
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Industry Trade Show
Not Confirmed
12-14 January, 2026
Digital content
NEWS #PharmaBuzz
16 Dec 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251216065234/en/Cosette-Pharmaceuticals-Announces-the-Approval-and-Launch-of-First-Generic-Version-of-CIPRO-HC-ciprofloxacin-0.2-HCl-and-hydrocortisone-1-otic-suspension-with-180-days-Competitive-Generic-Therapy-CGT-exclusivity
11 Dec 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251211144905/en/Termination-of-Proposed-Acquisition-of-Mayne-Pharma
21 Nov 2025
// FIERCE PHARMA
https://www.fiercepharma.com/pharma/australian-government-rejects-cosettes-proposed-mayne-pharma-buyout-citing-national-interest
10 Nov 2025
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=218273
10 Nov 2025
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218273
15 Oct 2025
// REUTERS
https://www.reuters.com/business/healthcare-pharmaceuticals/cosettes-attempt-drop-438-million-mayne-pharma-deal-denied-by-court-2025-10-15/
Drugs in Development
Details:
Ciprofloxacin HCl, an antibiotic targeting bacterial DNA gyrase and Topoisomerase IV, shows promise in treating Acute Otitis Externa.
Lead Product(s): Ciprofloxacin Hydrochloride,Hydrocortisone
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Brand Name: Cipro HC-Generic
Study Phase: Approved FDFProduct Type: Antibiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 16, 2025
Lead Product(s) : Ciprofloxacin Hydrochloride,Hydrocortisone
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Cosette Pharmaceuticals Launches First Generic CIPRO® HC with 180-day CGT Exclusivity
Details : Ciprofloxacin HCl, an antibiotic targeting bacterial DNA gyrase and Topoisomerase IV, shows promise in treating Acute Otitis Externa.
Product Name : Cipro HC-Generic
Product Type : Antibiotic
Upfront Cash : Inapplicable
December 16, 2025
Details:
Bremelanotide is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Lead Product(s): Bremelanotide Acetate
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Protein
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 10, 2025
Lead Product(s) : Bremelanotide Acetate
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Bremelanotide is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 10, 2025
Details:
Through the acquisition, Cosette will utilize market-leading commercial products focused on women’s health, including Annovera (segesterone acetate & ethinyl estradiol) to prevent preganancy.
Lead Product(s): Segesterone Acetate,Ethinyl Estradiol
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Annovera
Study Phase: Approved FDFProduct Type: Steroid
Recipient: Mayne Pharma
Deal Size: $430.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition February 20, 2025
Lead Product(s) : Segesterone Acetate,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Recipient : Mayne Pharma
Deal Size : $430.0 million
Deal Type : Acquisition
Cosette Pharmaceuticals Acquires Mayne Pharma for Women’s Health Leadership
Details : Through the acquisition, Cosette will utilize market-leading commercial products focused on women’s health, including Annovera (segesterone acetate & ethinyl estradiol) to prevent preganancy.
Product Name : Annovera
Product Type : Steroid
Upfront Cash : Undisclosed
February 20, 2025
Details:
Cosette Pharmaceuticals Acquires Ambien (Zolpidem Tartrate) Tablet from Sanofi US. It is indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation.
Lead Product(s): Zolpidem Tartrate
Therapeutic Area: Sleep Brand Name: Ambien
Study Phase: Approved FDFProduct Type: Controlled Substance
Recipient: Sanofi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 10, 2024
Lead Product(s) : Zolpidem Tartrate
Therapeutic Area : Sleep
Highest Development Status : Approved FDF
Recipient : Sanofi
Deal Size : Undisclosed
Deal Type : Acquisition
Cosette Acquires Ambien® and Ambien CR® from Sanofi US
Details : Cosette Pharmaceuticals Acquires Ambien (Zolpidem Tartrate) Tablet from Sanofi US. It is indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation.
Product Name : Ambien
Product Type : Controlled Substance
Upfront Cash : Undisclosed
July 10, 2024
Details:
Rectiv-Generic (nitroglycerin) is a nitrate vasodilator activating guanylate cyclase to increase cyclic GMP in smooth muscle. It is indicated for treating moderate to severe chronic anal fissure pain.
Lead Product(s): Nitroglycerin
Therapeutic Area: Gastroenterology Brand Name: Rectiv-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 22, 2024
Lead Product(s) : Nitroglycerin
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Cosette Pharmaceuticals Announces Approval and Launch Of First Generic Rectiv®
Details : Rectiv-Generic (nitroglycerin) is a nitrate vasodilator activating guanylate cyclase to increase cyclic GMP in smooth muscle. It is indicated for treating moderate to severe chronic anal fissure pain.
Product Name : Rectiv-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 22, 2024
Details:
Cosette expands its women's health platform by acquiring Vyleesi (bremelanotide acetate), first as-needed treatment for premenopausal women with acquired generalized hypoactive sexual desire disorder.
Lead Product(s): Bremelanotide Acetate
Therapeutic Area: Psychiatry/Psychology Brand Name: Vyleesi
Study Phase: Approved FDFProduct Type: Peptide, Unconjugated
Recipient: Palatin Technologies
Deal Size: $171.0 million Upfront Cash: $12.0 million
Deal Type: Acquisition January 03, 2024
Lead Product(s) : Bremelanotide Acetate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Recipient : Palatin Technologies
Deal Size : $171.0 million
Deal Type : Acquisition
Cosette Pharmaceuticals Acquires Vyleesi® from Palatin Technologies
Details : Cosette expands its women's health platform by acquiring Vyleesi (bremelanotide acetate), first as-needed treatment for premenopausal women with acquired generalized hypoactive sexual desire disorder.
Product Name : Vyleesi
Product Type : Peptide, Unconjugated
Upfront Cash : $12.0 million
January 03, 2024
Details:
Cosette expands its women's health platform through divestment by adding Vyleesi, the first approved as-needed treatment for premenopausal women with acquired hypoactive sexual desire disorder.
Lead Product(s): Bremelanotide Acetate
Therapeutic Area: Psychiatry/Psychology Brand Name: Vyleesi
Study Phase: Approved FDFProduct Type: Peptide, Unconjugated
Recipient: Palatin Technologies
Deal Size: $171.0 million Upfront Cash: $12.0 million
Deal Type: Divestment January 02, 2024
Lead Product(s) : Bremelanotide Acetate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Recipient : Palatin Technologies
Deal Size : $171.0 million
Deal Type : Divestment
Palatin Completes Sale of Vyleesi to Cosette Pharmaceuticals for up to $171 mn
Details : Cosette expands its women's health platform through divestment by adding Vyleesi, the first approved as-needed treatment for premenopausal women with acquired hypoactive sexual desire disorder.
Product Name : Vyleesi
Product Type : Peptide, Unconjugated
Upfront Cash : $12.0 million
January 02, 2024
Details:
Through the divestment, Cosette will further expand its women's health platform by adding Vyleesi (bremelanotide acetate), the first and only as-needed treatment approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder.
Lead Product(s): Bremelanotide Acetate
Therapeutic Area: Psychiatry/Psychology Brand Name: Vyleesi
Study Phase: Approved FDFProduct Type: Peptide, Unconjugated
Recipient: Palatin Technologies
Deal Size: $171.0 million Upfront Cash: $12.0 million
Deal Type: Divestment December 20, 2023
Lead Product(s) : Bremelanotide Acetate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Recipient : Palatin Technologies
Deal Size : $171.0 million
Deal Type : Divestment
Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million
Details : Through the divestment, Cosette will further expand its women's health platform by adding Vyleesi (bremelanotide acetate), the first and only as-needed treatment approved for premenopausal women with acquired, generalized hypoactive sexual desire disorde...
Product Name : Vyleesi
Product Type : Peptide, Unconjugated
Upfront Cash : $12.0 million
December 20, 2023
Details:
Dapsone (metronidazole) is a vaginal gel, generic version of MetroGel-Vaginal by Bausch Health, and is indicated for the topical treatment of inflammatory lesions of rosacea.
Lead Product(s): Metronidazole
Therapeutic Area: Infections and Infectious Diseases Brand Name: Dapsone
Study Phase: Approved FDFProduct Type: Plant Extract/Herbal
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 27, 2023
Lead Product(s) : Metronidazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Cosette Pharmaceuticals Launches Metronidazole Vaginal Gel 0.75%, AB-rated to MetroGel-Vaginal® 0...
Details : Dapsone (metronidazole) is a vaginal gel, generic version of MetroGel-Vaginal by Bausch Health, and is indicated for the topical treatment of inflammatory lesions of rosacea.
Product Name : Dapsone
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
July 27, 2023
Details:
Aczone contains dapsone, a sulfone, in an aqueous gel base indicated for the topical treatment of acne vulgaris. It works by killing or preventing the growth of bacteria on the skin.
Lead Product(s): Dapsone
Therapeutic Area: Dermatology Brand Name: Aczone-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: SeegPharm
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 13, 2023
Lead Product(s) : Dapsone
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : SeegPharm
Deal Size : Inapplicable
Deal Type : Inapplicable
Cosette Pharmaceuticals Launches Dapsone 5% Gel, AB-Rated to Aczone 5%
Details : Aczone contains dapsone, a sulfone, in an aqueous gel base indicated for the topical treatment of acne vulgaris. It works by killing or preventing the growth of bacteria on the skin.
Product Name : Aczone-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 13, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Share 
